Connection

David Potter to Humans

This is a "connection" page, showing publications David Potter has written about Humans.
Connection Strength

0.074
  1. Ketamine: repurposing and redefining a multifaceted drug. Drug Discov Today. 2014 Dec; 19(12):1848-54.
    View in: PubMed
    Score: 0.018
  2. Non-analgesic effects of opioids: neuroprotection in the retina. Curr Pharm Des. 2012; 18(37):6101-8.
    View in: PubMed
    Score: 0.015
  3. The opioidergic system: potential roles and therapeutic indications in the eye. J Ocul Pharmacol Ther. 2008 Apr; 24(2):117-40.
    View in: PubMed
    Score: 0.012
  4. Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS Drug Rev. 2005; 11(2):195-212.
    View in: PubMed
    Score: 0.009
  5. Functional identification of phosphodiesterase activity in human trabecular meshwork cells. J Ocul Pharmacol Ther. 2000 Aug; 16(4):317-22.
    View in: PubMed
    Score: 0.007
  6. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1999 Jul; 40(8):1745-52.
    View in: PubMed
    Score: 0.006
  7. Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys. Curr Eye Res. 1982-1983; 2(5):281-8.
    View in: PubMed
    Score: 0.002
  8. Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs. 2002; 171(2-3):188-98.
    View in: PubMed
    Score: 0.002
  9. Adrenergic pharmacology of aqueous humor dynamics. Pharmacol Rev. 1981 Sep; 33(3):133-53.
    View in: PubMed
    Score: 0.002
  10. Adrenergic drugs and intraocular pressure. Gen Pharmacol. 1981; 12(1):1-13.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.